Deja Bioconsult: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Deja Bioconsult
Largest movements
- Current investments +€35,000
new in 2025: €35,000
- Cash -€34,023
down €34,023 (-17.4%), from €196,081 to €162,058
mainly Contributions, distributions and other (-€180,940) and Current investments (-€35,000)
- Deferred charges and accrued income -€4,483
down €4,483 (-100%), from €4,483 to €0
- Reserves -€86,282
down €86,282 (-47.7%), from €180,940 to €94,659
- Other debts +€79,961
up €79,961 (+3,253%), from €2,458 to €82,419
- Gross operating margin +€3,471
up €3,471 (+2.9%), from €120,539 to €124,010
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €221,121 | €217,596 | -€3,524 | -1.6% |
| Fixed assets | 21/28 | €2,261 | €1,372 | -€889 | -39.3% |
| Tangible fixed assets | 22/27 | €2,261 | €1,372 | -€889 | -39.3% |
| Furniture and vehicles | 24 | €2,261 | €1,372 | -€889 | -39.3% |
| Current assets | 29/58 | €218,860 | €216,224 | -€2,636 | -1.2% |
| Amounts receivable within one year | 40/41 | €18,295 | €19,166 | +€871 | +4.8% |
| Trade receivables | 40 | €18,295 | €19,166 | +€871 | +4.8% |
| Current investments | 50/53 | - | €35,000 | +€35,000 | |
| Cash at bank and in hand | 54/58 | €196,081 | €162,058 | -€34,023 | -17.4% |
| Deferred charges and accrued income | 490/1 | €4,483 | €0 | -€4,483 | -100% |
| Total equity and liabilities | 10/49 | €221,121 | €217,596 | -€3,524 | -1.6% |
| Equity | 10/15 | €181,940 | €95,659 | -€86,282 | -47.4% |
| Contributions | 10/11 | €1,000 | €1,000 | = | 0.0% |
| Reserves | 13 | €180,940 | €94,659 | -€86,282 | -47.7% |
| Distributable reserves | 133 | €180,940 | €94,659 | -€86,282 | -47.7% |
| Profit (loss) carried forward | 14 | - | €0 | = | |
| Amounts payable | 17/49 | €39,180 | €121,937 | +€82,757 | +211% |
| Amounts payable within one year | 42/48 | €39,180 | €121,937 | +€82,757 | +211% |
| Trade debts | 44 | €489 | €1,559 | +€1,070 | +219% |
| Suppliers | 440/4 | €489 | €1,559 | +€1,070 | +219% |
| Taxes, remuneration and social security | 45 | €36,233 | €37,959 | +€1,726 | +4.8% |
| Taxes | 450/3 | €36,233 | €37,959 | +€1,726 | +4.8% |
| Other amounts payable | 47/48 | €2,458 | €82,419 | +€79,961 | +3,253% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €405 | €889 | +€483 | +119% |
| Other operating charges | 640/8 | €700 | €672 | -€28 | -4.0% |
| Gross operating margin | 9900 | €120,539 | €124,010 | +€3,471 | +2.9% |
| Operating profit (loss) | 9901 | €119,434 | €122,449 | +€3,016 | +2.5% |
| Financial income | 75/76B | €2 | €0 | -€2 | -100% |
| Recurring financial income | 75 | €2 | €0 | -€2 | -100% |
| Financial charges | 65/66B | €1,013 | €1,150 | +€137 | +13.6% |
| Recurring financial charges | 65 | €1,013 | €1,150 | +€137 | +13.6% |
| Profit (loss) for the period before taxes | 9903 | €118,423 | €121,299 | +€2,876 | +2.4% |
| Income taxes | 67/77 | €25,443 | €26,640 | +€1,198 | +4.7% |
| Profit (loss) for the period | 9904 | €92,980 | €94,659 | +€1,679 | +1.8% |
| Profit (loss) for the period to be appropriated | 9905 | €92,980 | €94,659 | +€1,679 | +1.8% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 19 October 2026 via checked.be.